1 Sep 2020 07:52
For immediate release | 01 September 2020 |
ABCAM PLC
("Abcam" or "Company")
Total Voting Rights - Voting Rights and Capital
In conformity with the Disclosure Rules and Transparency Rules, provision 5.6.1, the Company notifies the market of the following: The Company's issued share capital consists of 216,192,416 Ordinary Shares of 0.2p each with voting rights. The Company does not hold any shares in Treasury.The above figure of 216,192,416 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.
Date of Notification: 01 September 2020.
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Marc Perkins, Company Secretary
| |
Numis - Nominated Adviser & Joint Corporate Broker | + 44 (0) 20 7260 1000 |
Garry Levin / Huw Jeremy | |
J.P.Morgan Cazenove - Joint Corporate Broker James Mitford / Hemant Kapoor |
+44 (0) 20 7742 4000 |
Morgan Stanley - Joint Corporate Broker Tom Perry / Luka Kezic |
+44 (0) 20 425 8000 |
FTI Consulting Ben Atwell / Natalie Garland-Collins |
+44 (0) 20 3727 1000 |
Notes to Editors
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.
By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Abcam's thirteen locations are in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and www.abcamplc.com